Radioembolization of hepatocellular carcinoma

Current Drug Discovery Technologies

Volumn 7, Issue 4, 2010, Pages 247-252

  Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

131I Lipiodol; HCC; Radioembolization; SIR spheres; Therasphere

Indexed keywords

CISPLATIN; GLASS; LIPIODOL IODINE I 131; MICROSPHERE; RADIOPHARMACEUTICAL AGENT; RESIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; ARTIFICIAL EMBOLISM; BONE MARROW TOXICITY; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; HUMANS; LIVER NEOPLASMS; MICROSPHERES; RADIOPHARMACEUTICALS; SURVIVAL; YTTRIUM RADIOISOTOPES;

EID: 78650728202     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310793360701     Document Type: Article

References (44)

1. Parkin MD, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Monto A, Wright TL. Epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001; 28: 441-9.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362; 1907-17.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Eng J Med 1996; 334: 693-9.
5. Llovet M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
6. Dusheiko GM, Hobbs KE, Dick R, Buroughs AK. Treatment of small hepatocellular carcinomas. Lancet 1992; 340: 285-8.
7. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001; 28(5): 503-13.
8. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28(5): 514-20.
9. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of soraf-enib in patients in the Asia-Pacific region with advanced hepatocel-lular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
10. Cheng JC, Wud JK, Huanga CM, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 2002; 63: 41-5.
11. Bierman HR, Byron RL Jr., Kelley KH, Grady A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic angiography in vivo. J Natl Cancer Inst 1951; 12: 107-31.
12. Lambert B, Van de Wiele C. Selective internal radiation therapy of HCC and liver metastases: a locoregional or worldwide therapy. Q J Nucl Med Mol Imaging 2009; 53: 302-4.
13. Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2005; 32: 980-9.
14. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepato-cellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985; 154: 15-7.
15. Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver endo-thelial cells incorporate iodised oil. Br J Cancer 1996; 73: 877-81.
16. Kobayashi H, Hidaka H, Kajiya Y, et al. Treatment of hepatocellu-lar carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn (Stockh) 1986; 27: 139-47.
17. Raoul JL , Bourget P, Bretagne JF, et al. Hepatic artery injection of I131 labelled lipiodol. I. Biodistribution study results in patients with hepatocellular carcinoma. Radiology 1988; 168: 541-5.
18. Nakajo L, Kobayashi H, Shimabukuro K, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancers. J Nucl Med 1988; 29: 1066-77.
19. Madsen MT, Park CH, Thakur ML. Dosimetry of iodine-131 ethio-dol in the treatment of hepatoma. J Nucl Med 1988; 29: 1038-44.
20. Bretagne JF, Raoul JL, Bourguet P, et al. Hepatic artery injection of I131 labelled lipiodol. II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 547-50.
21. 131I-lipiodol. Cancer 1992; 69: 346-52.
22. Raoul JL, Guyader D, Bretagne JF, et al. Radndomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: in-tra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 1782-7.
23. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemo-embolization vs. intra-arterial injection of I131 labelled iodized oil in the treatment of hepatocellular carcinoma. He-patology 1997; 26: 1156-61.
24. Boucher E, Garin E, Guillygoma'ch A, Olivie D, Boudjema K, Raoul JL. Intra-arterial injection of iodine-131-labeled lipidol for treatment of hepatocellular carcinoma. Radiother Oncol 2007; 82: 76-82.
25. Yoo HS, Lee JT, Kim BS, et al. Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeld iodize oil. Cancer 1991; 68: 1878-84.
26. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353: 797-801.
27. Boucher E, Bouguen G, Garin E, Guillygomac'h A, Boudjema K, Raoul JL. Adjuvant intra-arterial injection of iodine 131-labelled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5 year minimal follow-up. J Nucl Med 2008; 49: 362-6.
28. Tabone M, Vigano L, Laudi C, Ferrero A, Pellerito R, Capussotti L. Adjuvant iodine-131-labelled lipiodol for prevention of intrahe-patic recurrence of hepatocellular carcinoma : which is the best treatment schedule. Hepatology 2005; 1433.
29. 131I-lipiodol. Br J Surg 2003; 90: 137983.
30. 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun 2003; 24: 671-8.
31. Liu D, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16: 911-35.
32. Houle S, Yip T, Shepherd F, et al. Hepatocellular carcinoma: pilot trial of treatment with 90Y-microspheres. Radiology 1989; 172: 857-60.
33. Dancey Y, Shepherd F, Paul K, et al. Treatment of n onresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41: 1673-81.
34. Carr B. Hepatic arterial glass microspheres (Therasphere) for unre-sectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplant 2004: 10(Suppl2): S107-S110.
35. Geschwind JF, Salem R, Carr B, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127: S195-S205.
36. Salem R, Lewandowski R, Atassi B, et al. Treatment of unre-sectable hepatocellular carcinoma with use of 90Y-microspheres (Therasphere): safety, tumor response and survival. J Vasc Interv Radiol 2005; 16: 1627-39.
37. Kulik L, Atassi B, Van Holsbeeck L, et al. Yttrium-90 microsphere treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-86.
38. Lewandowski Rj, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-8.
39. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Car-diovasc Intervent Radiol 2006; 29: 522-9.
40. Riaz A, Gates VL, Atassi B, et al. Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioemboliza-tion. Int J Radiat Oncol Biol Phys 2010 [Epub ahead of print].
41. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
42. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepato-cellular carcinoma with intrahepatic arterial yttrium-90 micro-spheres: a phase I and II study. Br J Cancer 1994; 70: 994-9.
43. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intra-arterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40: 583-92.
44. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24: 293-8.